Keto Diet Outperforms Mediterranean and Low-Fat Diets in Reducing Liver Fat and Prediabetes

<>

• Dramatic Hepatic Lipid Reduction: The ketogenic diet achieved a 67% reduction in liver fat, compared to 45% for both the Mediterranean and low-fat diets.
• Prediabetes Reversal: Approximately 50% of participants on the keto diet no longer met clinical criteria for prediabetes after four to five months.
• Identical Weight Loss Margins: All three dietary groups achieved a roughly 10% reduction in total body weight, pointing to specific metabolic mechanisms beyond weight loss alone.

Clinical Trial Design and Patient Demographics

The randomized trial enrolled 42 participants diagnosed with obesity, prediabetes, and fatty liver disease. Investigators randomly assigned the cohort to one of three nutritional interventions: a ketogenic diet, a Mediterranean diet, or a low-fat, plant-forward diet. To ensure strict dietary adherence, researchers supplied all food and scheduled weekly dietitian visits throughout the intervention period. Caloric intake was individually adjusted across all arms to ensure every participant achieved a targeted 10% reduction in body weight over a span of four to five months.

The macronutrient distribution varied significantly by group. The ketogenic diet derived 4% of total calories from carbohydrates, and 73% from fat. By contrast, the Mediterranean diet comprised 50% carbohydrates and 35% fat, while the plant-forward diet consisted of 70% carbohydrates and 15% fat. Funding for the clinical investigation was provided by the National Institutes of Health and the Foundation for Barnes-Jewish Hospital.

Pathophysiological Mechanisms and Metabolic Markers

While all three interventions successfully improved overall body fat composition and enhanced insulin sensitivity, the ketogenic diet yielded distinct metabolic shifts. Liver fat plummeted by 67% in the keto group, outperforming the 45% reduction seen in both the Mediterranean and plant-forward cohorts. Continuous 24-hour metabolic tracking revealed that participants on the ketogenic diet experienced the most substantial rise in glucagon—a peptide hormone secreted by the pancreas that promotes the oxidation and breakdown of stored hepatic lipids—alongside the sharpest decline in circulating blood insulin.

According to Samuel Klein, the study’s corresponding author at Washington University School of Medicine, the data indicate that restricting carbohydrate intake produces therapeutic effects on metabolism that exceed the benefits of weight loss alone. Max Petersen, the study’s first author, noted a striking safety outcome: despite consuming a diet consisting predominantly of fat, participants in the ketogenic group did not exhibit elevated serum lipid or cholesterol levels.

Glycemic Control and Prediabetes Remission Rates

The trial tracked glycemic markers to evaluate the reversal of prediabetes, a condition characterized by blood glucose levels higher than normal but below the diagnostic threshold for type 2 diabetes. Approximately 40% of adults in the United States live with obesity, making targeted glycemic interventions an urgent clinical priority. Following the four-to-five-month trial, about 50% of individuals in the ketogenic diet group no longer met the clinical criteria for prediabetes. This remission rate compared favorably to the Mediterranean group, where 29% of participants reversed prediabetes, and the plant-forward group, which saw a 7% remission rate.

Patients managing complex metabolic disorders, insulin resistance, or fatty liver disease require comprehensive oversight from qualified medical professionals. For individuals seeking tailored diagnostic evaluations or specialized treatment protocols, scheduling an assessment with a vetted Board-Certified Endocrinologist or consulting a clinical nutrition specialist through an accredited Metabolic Health Center ensures safe, evidence-based management of glycemic parameters and hepatic function.

The findings published in Cell Metabolism highlight the therapeutic utility of very low-carbohydrate nutritional models in addressing ectopic fat deposition and impaired glucose homeostasis. While the short-term outcomes demonstrate significant reductions in hepatic steatosis and improved insulin dynamics, researchers emphasize the necessity of longer-term longitudinal studies to evaluate the durability of these metabolic adaptations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

>